CTNM logo

CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

145
Mkt Cap
$510.7M
Volume
92,500.00
52W High
$16.33
52W Low
$3.35
PE Ratio
-7.25
CTNM Fundamentals
Price
$14.15
Prev Close
$13.66
Open
$13.66
50D MA
$13.29
Beta
0.56
Avg. Volume
244,651.06
EPS (Annual)
-$2.17
P/B
2.12
Rev/Employee
$0.00
$61.97
Loading...
Loading...
News
all
press releases
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·3d ago
News Placeholder
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·6d ago
News Placeholder
Contineum Therapeutics (CTNM) Projected to Post Earnings on Wednesday
Contineum Therapeutics (NASDAQ:CTNM) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·9d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Shares Up 7.5% - Time to Buy?
Contineum Therapeutics (NASDAQ:CTNM) Trading 7.5% Higher - Should You Buy...
MarketBeat·9d ago
News Placeholder
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·13d ago
News Placeholder
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·14d ago
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Brokerages
Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold rec...
MarketBeat·28d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% Higher - Still a Buy?
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% Higher - Still a Buy...
MarketBeat·2mo ago
<
1
2
...
>

Latest CTNM News

View
Top Discussions